Fig. 2: Clinical timeline and lymph node biopsy.
From: A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy
a The patient was originally diagnosed with stage III, grade 1–2 follicular lymphoma (FL) 9 years prior to CAR-T. Upon progression, he was treated with rituximab and achieved a partial response (PR) for 2.5 years before he relapsed with transformed disease. He was then treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 6 cycles with a complete response (CR) lasting 3 years. He was treated on a clinical trial (NCT03636503) with rituximab/avelumab/utomilumab combination immunotherapy, with a PR followed by progression after 6 months. He then received CAR-T therapy as third-line therapy. Yellow shading indicates time prior to CAR-T, blue shading indicates time post-CAR-T. b PET/CT image of the new lymphadenopathy presenting 2.5 years after CAR-T. c Representative immunohistochemistry images of T- and B-cell markers of the from a single core lymph node biopsy. d PET/CT image of spontaneous regression of the lymphadenopathy 6 weeks after initial scan.
